In addition, our pre-clinical results provide evidence that epigenetic therapy targeting BET proteins, alone or in combination with novel or standard therapies, may be a useful approach to improve outcomes and overcome resistance compared with current standard-of-care treatments for NSCLC patients. Here, DNER is linked to non-small cell lung carcinoma.